Day: November 13, 2021

Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Cancers at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Cancers at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Tumor Infiltrating Lymphocyte (TIL) Cell Therapy in Combination with Pembrolizumab in Immune-Checkpoint Inhibitor Naïve Patients Shows Overall Response Rate (ORR) of 57% in Cervical Cancer, 60% in Melanoma with 30% Complete Response (CR) and 39% in Head and Neck Cancer SITC Update Conference Call and Webcast on Saturday, November 13 at 5:30 pm ET SAN CARLOS, Calif. and WASHINGTON, Nov. 13, 2021 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced clinical data for lifileucel in combination with pembrolizumab in patients with advanced cancers were presented in an oral session at the Society for Immunotherapy of Cancer (SITC) Annual Meeting. A slide presentation is also available on the Iovance website. Clinical data...

Continue reading

Video Release — Virginia-Class Attack Submarine New Jersey (SSN 796) Christened at Newport News Shipbuilding

Video Release — Virginia-Class Attack Submarine New Jersey (SSN 796) Christened at Newport News Shipbuilding

NEWPORT NEWS, Va., Nov. 13, 2021 (GLOBE NEWSWIRE) — Huntington Ingalls Industries (NYSE: HII) today christened pre-commissioning unit New Jersey (SSN 796) at the company’s Newport News Shipbuilding division. “The christening is a Navy and shipbuilder tradition that celebrates the hard work and dedication of the women and men who are building this magnificent submarine, readying her for the next phase of construction, which includes launch, testing, sea trials and delivery to the Navy,” said Jennifer Boykin, president of Newport News Shipbuilding. “We commemorate these American builders during a challenging time in our nation’s history.” “When New Jersey joins the Navy’s fleet, she will deliver firepower for freedom, taking with her the skill of her shipbuilders, the spirit of her sponsor, the courage of her commander and crew and...

Continue reading

NextCure and Collaborators Provide Clinical and Research Updates on NC318 and NC410 Candidates at Society for Immunotherapy of Cancer Annual Meeting

NextCure and Collaborators Provide Clinical and Research Updates on NC318 and NC410 Candidates at Society for Immunotherapy of Cancer Annual Meeting

BELTSVILLE, Md., Nov. 13, 2021 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced new data from two clinical studies and one research study presented at the Society for Immunotherapy of Cancer (SITC) annual meeting in Washington, D.C., and on a virtual platform. The data come from clinical studies evaluating NC318, a Siglec-15 (S15) antibody, and NC410, a fusion protein of LAIR-2, in patients with advanced/metastatic solid tumors, as well as from a research study evaluating NC410’s impact on T cell activation and myeloid cell polarization conducted in collaboration with the National Cancer Institute at the National Institutes of Health. “We are...

Continue reading

Aadi Bioscience Presents Two Abstracts on FYARRO (nab-Sirolimus) at the Annual Meeting of the Connective Tissue Oncology Society (CTOS)

Aadi Bioscience Presents Two Abstracts on FYARRO (nab-Sirolimus) at the Annual Meeting of the Connective Tissue Oncology Society (CTOS)

In an Expanded Access Program, advanced malignant PEComa patients who previously progressed on other mTOR inhibitors showed a 25% partial response rate and 63% clinical benefit rate when treated with nab-sirolimus In a final analysis from the AMPECT registrational trial in mTOR naïve patients with advanced malignant PEComa, results of a 2.5 year-follow-up showed a median duration of response exceeding 36 months and conversion of 2 patients to complete responses FYARRO™ has a November 26, 2021 PDUFA target date LOS ANGELES, Nov. 13, 2021 (GLOBE NEWSWIRE) — Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced two oral presentations that were made related to its lead candidate,...

Continue reading

Outlook Therapeutics Presents NORSE TWO Phase 3 Pivotal Safety and Efficacy Data for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) at the Retina Subspecialty Day, American Academy of Ophthalmology (AAO) 2021 Annual Conference

Outlook Therapeutics Presents NORSE TWO Phase 3 Pivotal Safety and Efficacy Data for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) at the Retina Subspecialty Day, American Academy of Ophthalmology (AAO) 2021 Annual Conference

– NORSE TWO showed highly statistically significant, clinically relevant results consistent with historical ophthalmic bevacizumab data – Data support planned BLA submission with U.S. FDA in Q12022 ISELIN, N.J., Nov. 13, 2021 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today presented pivotal safety and efficacy data from the Phase 3 NORSE TWO trial for ONS-5010, an investigational ophthalmic formulation of bevacizumab for use in wet age-related macular degeneration (wet AMD) and other retinal indications, at the Retinal Subspecialty Day, AAO 2021 Annual Conference. The data presentation “Safety and Efficacy Results of ONS-5010, as Ophthalmic Bevacizumab,...

Continue reading

Nexus REIT Announces Q3 2021 Results

Nexus REIT Announces Q3 2021 Results

TORONTO and MONTREAL, Nov. 12, 2021 (GLOBE NEWSWIRE) — Nexus Real Estate Investment Trust (the “REIT”) (TSX: NXR.UN) announced today its results for the quarter ended September 30, 2021. Highlights Occupancy of 95% at September 30, 2021, stable compared to June 30, 2021 and increased from 93% at September 30, 2020. Completed a total of $95.5MM of industrial property acquisitions during Q3 2021. Completed a total of $285.9MM of industrial acquisitions in October and November to date and completed due diligence and waived conditions to acquire a Class A distribution centre in Alberta for $15.25MM USD. The REIT’s acquisition pipeline continues to be very strong. Q3 2021 net operating income of $14,095,270 increased by $4,145,908 or 41.7% as compared to Q3 2020 net operating income of $9,949,362 and by $1,875,365 or 15.4%...

Continue reading

Cashbox Ventures Ltd. announces issuance pursuant to Consulting Agreement

Cashbox Ventures Ltd. announces issuance pursuant to Consulting Agreement

VANCOUVER, British Columbia, Nov. 12, 2021 (GLOBE NEWSWIRE) — Cashbox Ventures Ltd. (the “Company”) (CSE: CBOX) announces that it has entered into a Consulting Agreement whereby in exchange for services rendered over a twelve ‎month period, the Company issued a total of 1,750,000 common shares in the capital of ‎the Company (“Common Shares”), at a price of $0.045 per Common Shares. The Common Shares are ‎subject to a four-month hold period from the date of issuance in accordance with applicable securities ‎laws. With 50% of the Common Shares being subject to an additional 12 month hold from the date of issuance. About Cashbox Ventures Ltd. The Company recently divested all of its online platform assets. The business activities of the Company is expected to include the search and evaluation of new investment opportunities along...

Continue reading

Pinehurst Capital II Announces Letter of Intent for Qualifying Transaction with Halcones Precious Metals Inc.

Pinehurst Capital II Announces Letter of Intent for Qualifying Transaction with Halcones Precious Metals Inc.

TORONTO, Nov. 12, 2021 (GLOBE NEWSWIRE) — Pinehurst Capital II Inc. (TSXV: PINH.P) (the “Corporation” or “Pinehurst“), a capital pool company listed on the TSX Venture Exchange (“TSXV“), has entered into a binding letter of intent with Halcones Precious Metals Inc. (“Halcones”) dated November 12, 2021 (the “Letter of Intent“) in respect of a proposed business combination transaction pursuant to which Pinehurst will acquire all of the issued and outstanding securities of Halcones (the “Proposed Transaction”). It is anticipated that the Proposed Transaction will constitute the qualifying transaction of Pinehurst in accordance with Policy 2.4 – Capital Pool Companies of the Corporate Finance Manual (the “CPC Policy“) of the TSX Venture Exchange (the “TSXV”). The resulting...

Continue reading

PureGold Gold Reports Third Quarter 2021 Financial and Operating Results

PureGold Gold Reports Third Quarter 2021 Financial and Operating Results

VANCOUVER, British Columbia, Nov. 12, 2021 (GLOBE NEWSWIRE) — Pure Gold Mining Inc. (TSX-V:PGM, LSE:PUR) (“PureGold” or the “Company”), reports its third quarter 2021 summary financial and operating results. The Company’s unaudited condensed interim financial statements and related management’s discussion and analysis for the three and nine months ended September 30, 2021, will be available for download on SEDAR and on the Company’s website. All amounts are expressed in Canadian dollars (“$”), unless otherwise noted). A summary of the highlights for the three months ended September 30, 2021, and subsequent period to date for the Company and its 100% owned PureGold Mine Project (“PureGold Mine” or the “Project”) are as follows: Declared commercial production on August 1, 2021; Announced on October 27, 2021, that Maryse Bélanger,...

Continue reading

Ero Copper Files Technical Report for Boa Esperança Project

Ero Copper Files Technical Report for Boa Esperança Project

VANCOUVER, British Columbia, Nov. 12, 2021 (GLOBE NEWSWIRE) — Ero Copper Corp. (TSX: ERO, NYSE: ERO) (the “Company”) announces that it has filed the 2021 Technical Report regarding the optimized Feasibility Study and updated Mineral Reserve and Mineral Resource estimate for its Boa Esperança Project, the results of which were announced on September 28, 2021. The Technical Report was prepared in accordance with the Canadian Securities Administrator’s National Instrument 43-101 – Standards of Disclosure for Mineral Projects, and can be found on the Company’s website (www.erocopper.com) and on SEDAR (www.sedar.com). ABOUT ERO COPPER CORP Ero Copper Corp, headquartered in Vancouver, B.C., is focused on copper production growth from the MCSA Mining Complex located in Bahia State, Brazil, with over 40 years of operating history...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.